67. 多発性嚢胞腎 Polycystic kidney disease Clinical trials / Disease details

臨床試験数 : 221 / 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151

78 trials found

diseases per page:

Showing 1 to 10 of 78 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05190744 (ClinicalTrials.gov)	September 1, 2022	29/12/2021	PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Po ...	A Multi-center, Open-Label, Exploratory Study to Assess the Efficacy of PB in Decreasing the Urine O ...	Autosomal Dominant Polycystic Kidney Disease;Nephrogenic Diabetes Insipidus;Acquired Nephrogenic Dia ...	Drug: PB	Mayo Clinic	Hopital du Sacre-Coeur de Montreal	Recruiting	18 Years	N/A	All	20	Phase 2	United States
2	NCT04782258 (ClinicalTrials.gov)	July 15, 2022	19/2/2021	A Study to See if Tolvaptanis Safe in Infants and Children Who at Enrollment Are 28 Days to Less Tha ...	A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptanin Inf ...	Autosomal Recessive Polycystic Kidney (ARPKD)	Drug: Tolvaptan Suspension;Drug: Tolvaptan Tablets	Otsuka Pharmaceutical Development & Commercialization, Inc.	NULL	Recruiting	28 Days	18 Years	All	10	Phase 3	United States;Belgium;France;Germany;Italy;Poland;United Kingdom
3	NCT04786574 (ClinicalTrials.gov)	July 1, 2022	19/2/2021	A Study to See if TolvaptanCan Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days ...	A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptanin Inf ...	Autosomal Recessive Polycystic Kidney Disease (ARPKD)	Drug: Tolvaptan (OPC-41061)	Otsuka Pharmaceutical Development & Commercialization, Inc.	NULL	Recruiting	28 Days	12 Weeks	All	20	Phase 3	United States;Belgium;Germany;Italy;United Kingdom
4	JPRN-UMIN000046275	2021/12/11	06/12/2021	The effect of dapagliflozin in autosomal dominant polycystic kidney disease patients using tolvaptan ...	The effect of dapagliflozin in autosomal dominant polycystic kidney disease patients using tolvaptan ...	Autosomal dominant polycystic kidney disease (ADPKD)	Dapagliflozin 10mg/day for 6 months No treatment for 6 months	Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine	Department of Nephrology, International University of Health and Welfare School of MedicineDivision ...	Recruiting	20years-old	Not applicable	Male and Female	30	Not selected	Japan
5	NCT04152837 (ClinicalTrials.gov)	September 2, 2020	31/10/2019	Safety of Lixivaptan in Subjects Previously Treated With Tolvaptanfor Autosomal Dominant Polycystic ...	An Open-Label Study of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Who ...	Polycystic Kidney Disease, Adult;ADPKD	Drug: Lixivaptan	Palladio Biosciences	Centessa Pharmaceuticals plc	Terminated	18 Years	65 Years	All	7	Phase 3	United States
6	NCT03949894 (ClinicalTrials.gov)	July 1, 2019	16/4/2019	Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptanfor Managemen ...	Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptanfor Managemen ...	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Drug: Tolvaptan	Korea Otsuka Pharmaceutical Co., Ltd.	NULL	Completed	19 Years	50 Years	All	118	Phase 4	Korea, Republic of
7	JPRN-jRCTs031180259	01/04/2019	14/03/2019	Tolvaptan Intervention study and Genetic mutation of AutosomalDominant Polycystic Kidney Disease	TolvaptanIntervention study to Autosomal Dominant PolycysticKidney Disease patients without Genetic ...	ADPKD	Tolvaptan treatment	Horie Shigeo	NULL	Complete	>= 20age old	Not applicable	Both	10	N/A	Japan
8	NCT03764605 (ClinicalTrials.gov)	January 30, 2019	29/11/2018	Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease	Metformin vs Tolvaptanfor Treatment of Autosomal Dominant Polycystic Kidney Disease. A Phase 3a, Ind ...	ADPKD	Drug: Metformin;Drug: Tolvaptan	Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari	NULL	Not yet recruiting	18 Years	50 Years	All	150	Phase 3	Italy
9	NCT03541447 (ClinicalTrials.gov)	December 12, 2018	17/5/2018	Tolvaptan-Octreotide LAR Combination in ADPKD	A Pilot, Phase II Study With a Prospective, Randomized, Cross-Over, Placebo-Controlled, Double-Blind ...	Autosomal Dominant Polycystic Kidney Disease	Drug: Tolvaptan;Drug: Octreotide LAR;Other: Placebo	Mario Negri Institute for Pharmacological Research	Otsuka Pharmaceutical Italy S.r.l.	Completed	18 Years	N/A	All	20	Phase 2	Italy
10	EUCTR2018-000477-77-IT (EUCTR)	08/11/2018	04/11/2020	Evaluation of Metformin and Tolvaptanin slowing disease progression of Autosomal Dominant Polycystic ...	Metformin versus Tolvaptanin adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD): a pha ...	Autosomal Dominant Polycystic Kidney Disease MedDRA version: 20.0;Level: LLT;Classification code 100 ...	Trade Name: ZUGLIMET - 500 MG COMPRESSE RIVESTITE CON FILM 30 COMPRESSE IN BLISTER PVC/AL Product Nam ...	U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 3	Italy

First Previous1 2 3 4 5…8Next Last